Northwest Biotherapeutics is a biotechnology company developing personalized immune therapies for cancer using its DCVax platform technology. DCVax uses activated dendritic cells to mobilize a patient's own immune system against cancer. Its lead product, DCVax-L, targets operable solid tumors including glioblastoma multiforme (GBM). The company completed a 331-patient Phase III trial for GBM, published results in JAMA Oncology, and submitted a Marketing Authorization Application in the U.K. in December 2023.
Q2 FY2026 — expected 2026-08-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-03-31 | 2024-12-31 | 0001410578-25-000598 | EDGAR | 64K words |
| 2024-03-05 | 2023-12-31 | 0001410578-24-000133 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001410578-23-000185 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001410578-22-000244 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001104659-21-044832 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001104659-20-034145 | EDGAR | — |
| 2019-04-02 | 2018-12-31 | 0001144204-19-017803 | EDGAR | — |
| 2018-04-17 | 2017-12-31 | 0001144204-18-020971 | EDGAR | — |
| 2017-04-17 | 2016-12-31 | 0001144204-17-020754 | EDGAR | — |
| 2016-03-16 | 2015-12-31 | 0001144204-16-088301 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001104659-25-112676 | EDGAR | 23K words |
| 2025-08-14 | 2025-06-30 | 0001410578-25-001825 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001410578-25-001333 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001410578-24-001879 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001410578-24-001278 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001410578-24-000741 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001410578-23-002304 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001410578-23-001633 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001410578-23-000976 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001410578-22-003073 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001410578-22-002177 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001410578-22-001218 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-01-15 | 0001104659-26-004146 | EDGAR | 1K words |
| 2026-01-02 | 0001104659-26-000243 | EDGAR | — |
| 2025-11-20 | 0001104659-25-114627 | EDGAR | — |
| 2025-10-31 | 0001104659-25-104812 | EDGAR | — |
| 2025-10-30 | 0001104659-25-104427 | EDGAR | — |
| 2025-10-24 | 0001104659-25-102049 | EDGAR | — |
| 2025-10-14 | 0001104659-25-099196 | EDGAR | — |
| 2024-12-26 | 0001104659-24-131723 | EDGAR | — |
| 2024-11-01 | 0001104659-24-113553 | EDGAR | — |
| 2024-08-02 | 0001104659-24-085198 | EDGAR | — |
460 total filings indexed. 428 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001072379 |
| Ticker | NWBO |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report